• 2-D08 (2’,3’,4’-trihydroxyflavone): Precise SUMOylation Inhi

  2026-07-14

  2-D08 (2’,3’,4’-trihydroxyflavone) is a highly selective inhibitor of protein sumoylation that blocks SUMO transfer without affecting the E1 enzyme or ubiquitin pathways. Its unique mechanism enables precise studies of posttranslational modifications in cancer and mitophagy models. This review details its validated mechanism, usage parameters, and limitations in current research contexts.

• BODIPY 581/591 C11: Precision Lipid Peroxidation Sensing in

  2026-07-14

  Explore how BODIPY 581/591 C11, a ratiometric fluorescent probe, provides unprecedented precision for lipid peroxidation detection in live-cell studies of endothelial ferroptosis. This article delivers a deeper mechanistic and translational perspective informed by the latest diabetes-osteoporosis research.

• Olaparib (AZD2281): Optimizing DNA Damage Response Workflows

  2026-07-13

  Olaparib (AZD2281) is the gold standard PARP-1/2 inhibitor for BRCA-associated cancer research, enabling precise DNA damage response assays and advanced tumor radiosensitization studies. This article delivers step-by-step protocols, troubleshooting tips, and key insights from recent mechanistic studies, helping researchers maximize the compound’s selectivity and translational impact.

• Alda 1: ALDH2 Activator Enhances Cardiac Ischemia Research

  2026-07-13

  Alda 1, a potent ALDH2 activator from APExBIO, empowers researchers to dissect and optimize aldehyde detoxification pathways, with unique advantages for studying cardioprotection and radiation-induced skin injury. This article delivers actionable workflows, advanced troubleshooting, and interpretive guidance informed by cutting-edge cardiomyocyte proliferation research.

• Biomimetic mRNA Nanovaccines Target Neutrophils in Liver Can

  2026-07-12

  This study introduces a biomimetic mRNA nanovaccine platform that selectively targets and activates tumor-associated neutrophils in hepatocellular carcinoma. By engineering liposomes with CD300LD and encoding IL-36γ mRNA, the approach elicits potent anti-tumor immunity and significantly improves survival, offering a new paradigm for neutrophil-directed immunotherapy.

• L-Glutathione Reduced in Redox Metabolism: Beyond the Antiox

  2026-07-10

  Explore how L-Glutathione Reduced advances redox metabolism research, bridging oxidative stress modeling and targeted metabolic intervention. This review connects mechanistic science with emerging applications and assay strategy.

• Radicicol (SKU A4067): Reliable Hsp90 Inhibition in Cell Ass

  2026-07-09

  This article provides a scenario-driven, evidence-based guide for leveraging Radicicol (SKU A4067) in cell viability, proliferation, and cytotoxicity assays. Drawing on recent literature and validated workflow data, it addresses real laboratory challenges, with a focus on assay reproducibility, mechanistic clarity, and vendor reliability for biomedical researchers.

• Difloxacin HCl (SKU A8411): Reliable Solutions for Cell Assa

  2026-07-09

  This article provides an evidence-based exploration of Difloxacin HCl (SKU A8411) as a quinolone antimicrobial antibiotic for cell viability, proliferation, and cytotoxicity assays. By addressing real laboratory scenarios, we demonstrate how Difloxacin HCl delivers reproducible and sensitive results, supports multidrug resistance reversal, and stands out in vendor reliability. Researchers will gain actionable, literature-backed guidance for optimizing experimental workflows.

• HSP90-METTL3 Axis Regulates MYC m6A Modification in CRC

  2026-07-08

  This study uncovers how HSP90 stabilizes the m6A methyltransferase METTL3 in colorectal cancer, sustaining MYC mRNA methylation and expression. Inhibition of HSP90 by 17-AAG triggers CHIP-mediated degradation of METTL3, reducing MYC signaling and impairing tumor cell growth, suggesting new therapeutic avenues for CRC.

• Paroxetine Mesylate Suppresses Colorectal Cancer via MET/ERB

  2026-07-08

  This article examines the evidence that Paroxetine Mesylate, beyond its established role as a selective serotonin reuptake inhibitor, inhibits colorectal cancer cell proliferation and induces apoptosis by targeting MET and ERBB3 receptor tyrosine kinases. These findings support the growing interest in drug repurposing and highlight practical implications for translational oncology research.

• Hypoxia and Immunometabolism in Tumor Microenvironment: Mech

  2026-07-07

  This review dissects how hypoxia-driven metabolic reprogramming and immune metabolism shape the immunosuppressive tumor microenvironment (TME), fostering tumor progression and evasion. By clarifying the interplay of oxygen deprivation, nutrient competition, and immune cell function, the paper highlights emerging opportunities for tumor-targeted therapeutic strategies and the necessity for precise redox state analysis in cancer research.

• Ibrexafungerp Efficacy Against Fluconazole-Resistant Candida

  2026-07-07

  This study rigorously evaluated ibrexafungerp (MK 3118) against fluconazole-resistant Candida auris using both in vitro susceptibility testing and a delayed-therapy animal model. Findings highlight ibrexafungerp’s consistent activity and therapeutic potential for multidrug-resistant invasive candidiasis.

• MTT as a Benchmark In Vitro Cell Proliferation Assay Reagent

  2026-07-06

  MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) stands out as a high-purity, NADH-dependent oxidoreductase substrate for robust colorimetric cell viability assays. APExBIO’s MTT empowers precise workflow optimization across diverse applications, from angiogenesis research to translational oncology, with actionable troubleshooting and protocol insights.

• Cy3 NHS ester (non-sulfonated): Technical Guide for Protein

  2026-07-06

  Cy3 NHS ester (non-sulfonated) provides a reliable solution for covalent labeling of proteins, peptides, and oligonucleotides at primary amines, supporting sensitive detection workflows in biomedical imaging and quantitative assays. It is best suited for protocols where organic co-solvents are acceptable, and is not optimal for highly sensitive or delicate proteins that require fully aqueous labeling conditions.

• Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding

  2026-07-05

  This study reveals that naturally occurring angiotensin peptides, including Angiotensin III, can substantially enhance the binding affinity of the SARS-CoV-2 spike protein to the AXL receptor. These findings highlight a novel intersection between RAAS peptide biology and viral entry mechanisms, with implications for understanding COVID-19 pathogenesis and potential therapeutic targeting.

11536 records 1/770 page Next 12345 下5页 Last page